{
    "clinical_study": {
        "@rank": "1317", 
        "acronym": "ACTMM", 
        "arm_group": {
            "arm_group_label": "ACT PET/CT", 
            "arm_group_type": "Experimental", 
            "description": "Dual-tracer ACT/FDG PET/CT and WB-DCE-MRI at baseline (pretreatment), post-induction and post-ASCT (if eligible)"
        }, 
        "brief_summary": {
            "textblock": "Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT\n      PET/CT) may help detect lesions before treatment and evaluate response following therapy in\n      patients with from multiple myeloma (MM). This study aimed to prospectively assess the\n      clinical utility of ACT PET/CT in MM as compared to the commonly used\n      F18-fluorodeoxyglucose(FDG)."
        }, 
        "brief_title": "C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  at least 20 years of age\n\n          -  previously untreated\n\n          -  complete pre-treatment clinical staging including bone marrow examination\n\n          -  written informed consent to participate in the study\n\n        Exclusion Criteria:\n\n          -  concurrent active malignant tumor(s)\n\n          -  pregnant or breast feeding women\n\n          -  non-compliant to PET/CT or to MRI\n\n          -  marked renal impairment (contraindicated for contrast-enhanced MRI)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691300", 
            "org_study_id": "99-2177A"
        }, 
        "intervention": {
            "arm_group_label": "ACT PET/CT", 
            "description": "Old tracer but new indication", 
            "intervention_name": "ACT PET/CT", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "C11-acetate PET/CT", 
            "Multiple myeloma", 
            "Pretreatment staging", 
            "Response assessment"
        ], 
        "lastchanged_date": "September 27, 2012", 
        "location": {
            "contact": {
                "email": "sophieclin@gmail.com", 
                "last_name": "Chieh Lin, MD, PhD", 
                "phone": "+886 3 3281200", 
                "phone_ext": "3594"
            }, 
            "facility": {
                "address": {
                    "city": "Gueishan", 
                    "country": "Taiwan", 
                    "state": "Taoyuan county", 
                    "zip": "33305"
                }, 
                "name": "Chang Gung Memorial Hostpial"
            }, 
            "investigator": {
                "last_name": "Chieh Lin, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "1", 
        "official_title": "C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment", 
        "other_outcome": {
            "description": "Based on clinical follow-up (M-protein or FLC assay, bone marrow examination or imaging findings)", 
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "With 2 years of follow-up time"
        }, 
        "overall_official": {
            "affiliation": "Department of Molecular Imaging Center and Nuclear Medicine, Chang Gung Memorial Hospital", 
            "last_name": "Chieh Lin, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Department of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reference standards: bone marrow examination and whole-body dynamic contrast-enhanced MRI", 
            "measure": "Pretreatment lesion detection", 
            "safety_issue": "No", 
            "time_frame": "Within 2 weeks before initiation of therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691300"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reference standard: clinical response based on International Uniform Criteria and bone marrow examination if any", 
                "measure": "Post-induction response assessment", 
                "safety_issue": "No", 
                "time_frame": "Approximately 4 months after initiation of therapy depending on the regimen"
            }, 
            {
                "description": "Reference standard: clinical response based on International Uniform Criteria and bone marrow examination if any", 
                "measure": "Post-ASCT response assessment", 
                "safety_issue": "No", 
                "time_frame": "Approximately 3 months after ASCT"
            }
        ], 
        "source": "Chang Gung Memorial Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chang Gung Memorial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}